WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999042133) INHIBITORS OF COMPLEMENT ACTIVATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/042133    International Application No.:    PCT/US1999/003566
Publication Date: 26.08.1999 International Filing Date: 19.02.1999
Chapter 2 Demand Filed:    03.09.1999    
IPC:
A61K 38/00 (2006.01), C07K 16/40 (2006.01)
Applicants: TANOX, INC. [US/US]; 10301 Stella Link Houston, TX 77025 (US)
Inventors: FUNG, Michael, S., C.; (US).
SUN, Cecily, R., Y.; (US).
SUN, Bill, N., C.; (US)
Agent: MIRABEL, Eric, P.; Tanox, Inc. 10301 Stella Link Houston, TX 77025 (US)
Priority Data:
60/075,328 20.02.1998 US
Title (EN) INHIBITORS OF COMPLEMENT ACTIVATION
(FR) INHIBITEURS DE L'ACTIVATION DU COMPLEMENT
Abstract: front page image
(EN)The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab')¿2? and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, under Accession Number HB-12476.
(FR)La présente invention concerne des inhibiteurs du facteur D, qui se lient au facteur D et bloquent son activité fonctionnelle relative à l'activation du complément. Ces inhibiteurs comprennent des molécules d'anticorps, ainsi que des homologues, analogues et des formes modifiées ou dérivées de ceux-ci, comprenant des fragments d'immunoglobuline tels que Fab, (Fab')¿2? et Fv, de petites molécules, notamment des peptides, des oligonucléotides, des peptidomimétiques et des composés organiques. On a par ailleurs produit et appelé 166-32 un anticorps monoclonal se liant au facteur D et bloquant sa capacité à activer le complément. L'hybridome produisant cet anticorps a été déposé à la ' American Type Culture Collection', 10801 University Blvd., Manassas, Va 20110-2209, sous le numéro d'entrée HB-12476.
Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, FI, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)